Zevra Therapeutics
Christopher Lauderback has a strong background in the pharmaceutical industry with experience in various roles. Christopher began their career at New River Pharmaceuticals as a Senior Scientist and later became an Associate Director. Christopher then worked at Airbase Therapeutics as the Director of Product Development. Lauderback went on to join Sigma-Tau Pharmaceuticals as a Senior Manager, focusing on CMC. Most recently, they have served as the Vice President at KemPharm, Inc.
Christopher Lauderback completed their Bachelor of Science in Chemistry from Emory & Henry College from 1992 to 1996. Following this, they pursued a PhD in Chemistry from the University of Kentucky, completing it from 1996 to 2001.
This person is not in any offices
Zevra Therapeutics
1 followers
We are a rare disease therapeutics company leading with science to make life-changing therapeutics available to patients with significant unmet needs. We involve key thought leaders, physicians, patients, care partners, and advocacy groups in all of our clinical and regulatory development strategies. With a keen understanding that drug development often requires creative solutions, we have the insight and expertise to forge new pathways to success that others have missed. By following the data without bias, our transparent narratives and common-sense perspective have successfully overcome complex development challenges to make much-needed therapies available to patients. Nimble and dauntless, we push boundaries beyond what is thought to be possible and advance new therapies that have the potential to bring meaningful improvement to patients’ lives.